文献速递炎症性肠病消化内镜消化道肿瘤与早癌

炎症性肠病结直肠癌筛查的内镜模式疗效与安全性比较:系统综述与网状Meta分析

Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-12-13

该系统综述与网状Meta分析纳入26项随机对照试验共4159例炎症性肠病患者,比较6种高清内镜模式筛查结直肠肿瘤的疗效与安全性。高清色素内镜较高清白光内镜可能小幅提高异型增生检出(RR 1.42,95%CI 1.02-1.98,低确定性),其余模式证据确定性极低或无差异。

要点

  • 高清色素内镜较低确定性证据可能较多检出异型增生病变(RR 1.42,95%CI 1.02-1.98)。
  • 全光谱内镜与高清白光内镜可能无差异(RR 3.24,95%CI 0.66-15.87,低确定性)。
  • 其余模式证据确定性极低,无证据支持其作为替代方案。

核心结论

  • 高清色素内镜是唯一有低确定性证据显示较高清白光内镜可能检出更多异型增生病变的炎症性肠病监测模式。
  • 由于证据确定性极低,无证据支持其他任何内镜模式作为替代方案。

研究设计与样本

  • 系统综述与网状Meta分析,检索CENTRAL、ClinicalTrials.gov、Embase、MEDLINE和WHO数据库至2024年2月。
  • 纳入26项随机对照试验,共4159例炎症性肠病患者,比较6种内镜模式。
  • 主要结局为每例患者检出任何异型增生病变,证据确定性采用GRADE评估。

主要发现

  • 高清色素内镜较高清白光内镜可能小幅提高异型增生检出(低确定性,效应量小;RR 1.42,95%CI 1.02-1.98)。
  • 全光谱内镜与高清白光内镜可能无差异(低确定性;RR 3.24,95%CI 0.66-15.87)。
  • 高清白光内镜联合分段复查:RR 1.35,95%CI 0.66-2.77;自身荧光成像:RR 1.18,95%CI 0.55-2.57;高清虚拟色素内镜:RR 0.99,95%CI 0.69-1.43;均为极低确定性。
  • 敏感性分析支持上述发现。
  • 严重不良事件数据有限,无法进行Meta分析;2164例患者中报告2例严重事件(极低确定性)。

关键数值与推荐

  • 高清色素内镜较高清白光内镜:RR 1.42,95%CI 1.02-1.98(低确定性,效应量小)。
  • 全光谱内镜较高清白光内镜:RR 3.24,95%CI 0.66-15.87(低确定性)。
  • 高清白光内镜联合分段复查较高清白光内镜:RR 1.35,95%CI 0.66-2.77(极低确定性)。
  • 自身荧光成像较高清白光内镜:RR 1.18,95%CI 0.55-2.57(极低确定性)。
  • 高清虚拟色素内镜较高清白光内镜:RR 0.99,95%CI 0.69-1.43(极低确定性)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 严重不良事件数据有限,无法进行Meta分析。
  • 除高清色素内镜(低确定性)外,其他模式的证据确定性均为极低。
  • 高清色素内镜的获益为低确定性证据,效应量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Long-standing inflammatory bowel disease (IBD) increases the risk of colonic neoplasia, necessitating effective screening strategies. This network meta-analysis compared the efficacy and safety between different endoscopic modalities in the high-definition (HD) era. METHODS: We searched CENTRAL, ClinicalTrials.gov, Embase, MEDLINE, and WHO for randomized controlled trials (RCTs) comparing endoscopic modalities for screening colonoscopy in patients with IBD up to February 2024. The primary outcome was detection of any dysplastic lesion per patient. The certainty of the evidence was GRADE-assessed. RESULTS: A total of 26 RCTs involving 4159 participants were included, comparing 6 endoscopic modalities: HD white light endoscopy (HD-WLE), HD virtual chromoendoscopy (HD-VCE), HD dye-based chromoendoscopy (HD-DCE), HD-WLE with segmental re-inspection (SR), auto-fluorescence imaging (AFI), and full-spectrum endoscopy (FUSE). HD-DCE may have a small benefit in detecting dysplasia over HD-WLE (low certainty, small magnitude;: relative risk [RR], 1.42; 95% confidence interval [CI], 1.02-1.98). FUSE may be no different to HD-WLE (low certainty: RR, 3.24; 95% CI, 0.66-15.87). The other modalities were assessed as very low certainty (HD-WLE with SR: RR, 1.35; 95% CI, 0.66-2.77; AFI: RR, 1.18; 95% CI, 0.55-2.57; HD-VCE: RR, 0.99; 95% CI, 0.69-1.43). Sensitivity analyses supported these findings. Limited data on serious adverse events precluded meta-analysis; 2 serious events were reported among 2164 patients (very low certainty). CONCLUSIONS: HD-DCE is the only modality for IBD surveillance with evidence (low-certainty) demonstrating potential to detect more dysplastic lesions compared with HD-WLE. There was no evidence to support any of the other modalities as an alternative due to very low-certainty evidence.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sinopoulou V, Nigam GB, Gordon M, et al. Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol. 2024. PMID: 39675405. doi:10.1016/j.cgh.2024.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。